These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12198815)

  • 1. How does glucose generate oxidative stress in peripheral nerve?
    Obrosova IG
    Int Rev Neurobiol; 2002; 50():3-35. PubMed ID: 12198815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic neuropathy and oxidative stress.
    Pop-Busui R; Sima A; Stevens M
    Diabetes Metab Res Rev; 2006; 22(4):257-73. PubMed ID: 16506271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy.
    Low PA; Nickander KK; Tritschler HJ
    Diabetes; 1997 Sep; 46 Suppl 2():S38-42. PubMed ID: 9285497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Oxidative Stress in Diabetic Neuropathy: Generation of Free Radical Species in the Glycation Reaction and Gene Polymorphisms Encoding Antioxidant Enzymes to Genetic Susceptibility to Diabetic Neuropathy in Population of Type I Diabetic Patients.
    Babizhayev MA; Strokov IA; Nosikov VV; Savel'yeva EL; Sitnikov VF; Yegorov YE; Lankin VZ
    Cell Biochem Biophys; 2015 Apr; 71(3):1425-43. PubMed ID: 25427889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications.
    Obrosova IG
    Antioxid Redox Signal; 2005; 7(11-12):1543-52. PubMed ID: 16356118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
    Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
    Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications: neuropathy, pathogenetic considerations.
    Greene DA; Sima AA; Stevens MJ; Feldman EL; Lattimer SA
    Diabetes Care; 1992 Dec; 15(12):1902-25. PubMed ID: 1464245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy.
    Stevens MJ; Obrosova I; Cao X; Van Huysen C; Greene DA
    Diabetes; 2000 Jun; 49(6):1006-15. PubMed ID: 10866054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
    Obrosova IG; Pacher P; Szabó C; Zsengeller Z; Hirooka H; Stevens MJ; Yorek MA
    Diabetes; 2005 Jan; 54(1):234-42. PubMed ID: 15616034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.
    Song Z; Fu DT; Chan YS; Leung S; Chung SS; Chung SK
    Mol Cell Neurosci; 2003 Aug; 23(4):638-47. PubMed ID: 12932443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects.
    Stevens MJ; Feldman EL; Greene DA
    Diabet Med; 1995 Jul; 12(7):566-79. PubMed ID: 7554777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.
    Obrosova IG; Minchenko AG; Vasupuram R; White L; Abatan OI; Kumagai AK; Frank RN; Stevens MJ
    Diabetes; 2003 Mar; 52(3):864-71. PubMed ID: 12606532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options.
    Thornalley PJ
    Int Rev Neurobiol; 2002; 50():37-57. PubMed ID: 12198817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Perspective for the treatment of diabetic neuropathy: translation from molecular studies to bedside].
    Yagihashi S; Yamagishi S; Wada R
    Rinsho Shinkeigaku; 2005 Nov; 45(11):966-8. PubMed ID: 16447775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.